Clinical presentation and prognosis in MOG-antibody disease: a UK study.
Maciej Juryńczyk,Silvia Messina,Mark Woodhall,Naheed Raza,Rosie Everett,Adriana Roca-Fernandez,George Tackley,Shahd Hamid,Angela Sheard,Gavin L Reynolds,Saleel Chandratre,Cheryl Hemingway,Anu Jacob,Angela Vincent,M. Isabel Leite,Patrick Waters,Jacqueline Palace +16 more
TLDR
MOG-antibody disease has a moderate relapse risk, which might be mitigated by medium term immunosuppression at onset, and permanent disability occurs in about half of patients and more often involves sphincter and erectile functions than vision or mobility.Abstract:
See de Seze (doi:10.1093/brain/awx292) for a scientific commentary on this article. A condition associated with an autoantibody against MOG has been recently recognized as a new inflammatory disease of the central nervous system, but the disease course and disability outcomes are largely unknown. In this study we investigated clinical characteristics of MOG-antibody disease on a large cohort of patients from the UK. We obtained demographic and clinical data on 252 UK patients positive for serum immunoglobulin G1 MOG antibodies as tested by the Autoimmune Neurology Group in Oxford. Disability outcomes and disease course were analysed in more detail in a cohort followed in the Neuromyelitis Optica Oxford Service (n = 75), and this included an incident cohort who were diagnosed at disease onset (n = 44). MOG-antibody disease affects females (57%) slightly more often than males, shows no ethnic bias and typically presents with isolated optic neuritis (55%, bilateral in almost half), transverse myelitis (18%) or acute disseminated encephalomyelitis-like presentations (18%). In the total Oxford cohort after a median disease duration of 28 months, 47% of patients were left with permanent disability in at least one of the following: 16% patients had visual acuity ≤6/36 in at least one eye, mobility was limited in 7% (i.e. Expanded Disability Status Scale ≥ 4.0), 5% had Expanded Disability Status Scale ≥ 6.0, 28% had permanent bladder issues, 20% had bowel dysfunction, and 21% of males had erectile dysfunction. Transverse myelitis at onset was a significant predictor of long-term disability. In the incident cohort 36% relapsed after median disease duration of 16 months. The annualized relapse rate was 0.2. Immunosuppression longer than 3 months following the onset attack was associated with a lower risk of a second relapse. MOG-antibody disease has a moderate relapse risk, which might be mitigated by medium term immunosuppression at onset. Permanent disability occurs in about half of patients and more often involves sphincter and erectile functions than vision or mobility.read more
Citations
More filters
Journal ArticleDOI
MOG encephalomyelitis: International recommendations on diagnosis and antibody testing
Sven Jarius,Friedemann Paul,Friedemann Paul,Orhan Aktas,Nasrin Asgari,Russell C. Dale,J. de Seze,Diego Franciotta,Kazuo Fujihara,Anu Jacob,Ho Jin Kim,Ingo Kleiter,T. Kümpfel,Michael J. Levy,Jacqueline Palace,Klemens Ruprecht,Albert Saiz,Corinna Trebst,Brian G. Weinshenker,Brigitte Wildemann +19 more
TL;DR: In this article, the authors proposed indications for MOG-IgG testing based on expert consensus, and gave a list of conditions atypical for MG-EM (red flags) that should prompt physicians to challenge a positive MOG IgG test result, and provided recommendations regarding assay methodology, specimen sampling and data interpretation.
Journal ArticleDOI
Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis.
Divyanshu Dubey,Sean J. Pittock,Cecilia Kelly,Andrew McKeon,Alfonso Sebastian Lopez-Chiriboga,Vanda A. Lennon,Avi Gadoth,Carin Y. Smith,Sandra C. Bryant,Christopher J. Klein,Allen J. Aksamit,Michel Toledano,Bradley F. Boeve,Jan Mendelt Tillema,Eoin P. Flanagan +14 more
TL;DR: To evaluate the incidence and prevalence of autoimmune encephalitis and compare it to that of infectiousEncephalitis, a large number of patients with known or suspected cases of the disease are referred to a single hospital for evaluation.
MOG-Enzephalomyelitis: Internationale Empfehlungen zu Diagnose und Antikörpertestung [MOG encephalomyelitis: international recommendations on diagnosis and antibody testing]
Sven Jarius,Friedemann Paul,Orhan Aktas,Nasrin Asgari,Russell C. Dale,J. de Seze,Diego Franciotta,Kazuo Fujihara,Aude Jacob,Ho Jin Kim,I. Kleiter,T. Kümpfel,Michael J. Levy,Jacqueline Palace,Klemens Ruprecht,Albert Saiz,C. Trebst,Brian G. Weinshenker,B. Wildemann +18 more
TL;DR: Indications for MOG-IgG testing based on expert consensus are proposed and a list of conditions atypical for Mog-EM (“red flags”) are given that should prompt physicians to challenge a positive Mogenogenetically distinct test result.
Journal ArticleDOI
Myelin oligodendrocyte glycoprotein antibodies in neurological disease.
Markus Reindl,Patrick Waters +1 more
TL;DR: Antibodies against myelin oligodendrocyte glycoprotein (MOG-Abs) that are detectable with cell-based assays are associated with non-MS acquired demyelinating syndromes of the CNS, including the value of detection assays and evidence for antibody pathogenicity and its mechanism.
Journal ArticleDOI
Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.
Alvaro Cobo-Calvo,Anne Ruiz,Elisabeth Maillart,Bertrand Audoin,Hélène Zéphir,Bertrand Bourre,Jonathan Ciron,Nicolas Collongues,David Brassat,François Cotton,Caroline Papeix,Françoise Durand-Dubief,David Laplaud,Romain Deschamps,Mikael Cohen,Damien Biotti,Xavier Ayrignac,Caroline Tilikete,Eric Thouvenot,Bruno Brochet,Cécile Dulau,Thibault Moreau,Ayman Tourbah,Pierre Lebranchu,Laure Michel,Christine Lebrun-Frenay,Alexis Montcuquet,Guillaume Mathey,Marc Debouverie,Jean Pelletier,Pierre Labauge,Nathalie Derache,M. Coustans,Fabien Rollot,Jérôme De Seze,Sandra Vukusic,Romain Marignier +36 more
TL;DR: In adults, MOG-Ab-associated disease extends beyond clinical and radiologic abnormalities in the optic nerve and spinal cord and despite the relapsing course, the overall visual and motor outcome is better compared with AQP4- Ab-positive patients.
References
More filters
Journal ArticleDOI
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman,Stephen C. Reingold,Brenda Banwell,Michel Clanet,Jeffrey A. Cohen,Massimo Filippi,Kazuo Fujihara,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,Fred D. Lublin,Xavier Montalban,Paul L. O’Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Emmanuelle Waubant,Brian G. Weinshenker,Jerry S. Wolinsky +17 more
TL;DR: These revisions simplify the McDonald Criteria, preserve their diagnostic sensitivity and specificity, address their applicability across populations, and may allow earlier diagnosis and more uniform and widespread use.
Journal ArticleDOI
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk,Brenda Banwell,Jeffrey Bennett,Philippe Cabre,William M. Carroll,Tanuja Chitnis,Jérôme De Seze,Kazuo Fujihara,Benjamin Greenberg,Anu Jacob,Sven Jarius,Marco Aurélio Lana-Peixoto,Michael J. Levy,Jack H. Simon,Silvia Tenembaum,Anthony Traboulsee,Patrick Waters,Kay E. Wellik,Brian G. Weinshenker +18 more
TL;DR: The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and electronic surveys to facilitate consensus and achieved consensus on pediatric NMOSD diagnosis and the concepts of monophasicNMOSD and opticospinal MS.
Journal ArticleDOI
Revised diagnostic criteria for neuromyelitis optica
TL;DR: Revised diagnostic criteria for definite neuromyelitis optica (NMO) that require optic neuritis, myelitis, and at least two of three supportive criteria: MRI evidence of a contiguous spinal cord lesion 3 or more segments in length, onset brain MRI nondiagnostic for multiple sclerosis, or NMO-IgG seropositivity.
Journal ArticleDOI
The spectrum of neuromyelitis optica
Dean M. Wingerchuk,Vanda A. Lennon,Claudia F. Lucchinetti,Sean J. Pittock,Brian G. Weinshenker +4 more
TL;DR: Data suggest that autoantibodies to aquaporin 4 derived from peripheral B cells cause the activation of complement, inflammatory demyelination, and necrosis that is seen in neuromyelitis optica.
Journal ArticleDOI
International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions
Lauren B. Krupp,Marc Tardieu,Maria Pia Amato,Brenda Banwell,Tanuja Chitnis,Russell C. Dale,Angelo Ghezzi,Rogier Q. Hintzen,Andrew J. Kornberg,Daniela Pohl,Kevin Rostasy,Silvia Tenembaum,Evangeline Wassmer +12 more
TL;DR: Revised criteria are proposed for pediatric acute disseminated encephalomyelitis, pediatric clinically isolated syndrome, pediatric neuromyELitis optica and pediatric MS to incorporate advances in delineating the clinical and neuroradiologic features of these disorders.
Related Papers (5)
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
Sven Jarius,Klemens Ruprecht,Ingo Kleiter,Nadja Borisow,Nasrin Asgari,Kalliopi Pitarokoili,Florence Pache,Oliver Stich,Lena-Alexandra Beume,Martin W. Hümmert,Marius Ringelstein,Corinna Trebst,Alexander Winkelmann,Alexander Schwarz,Mathias Buttmann,Hanna Zimmermann,Joseph Kuchling,Diego Franciotta,Marco Capobianco,Eberhard Siebert,Carsten Lukas,Mirjam Korporal-Kuhnke,Jürgen Haas,Kai Fechner,Alexander U. Brandt,Kathrin Schanda,Orhan Aktas,Friedemann Paul,Markus Reindl,Brigitte Wildemann +29 more
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk,Brenda Banwell,Jeffrey Bennett,Philippe Cabre,William M. Carroll,Tanuja Chitnis,Jérôme De Seze,Kazuo Fujihara,Benjamin Greenberg,Anu Jacob,Sven Jarius,Marco Aurélio Lana-Peixoto,Michael J. Levy,Jack H. Simon,Silvia Tenembaum,Anthony Traboulsee,Patrick Waters,Kay E. Wellik,Brian G. Weinshenker +18 more
Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
MOG encephalomyelitis: International recommendations on diagnosis and antibody testing
Sven Jarius,Friedemann Paul,Friedemann Paul,Orhan Aktas,Nasrin Asgari,Russell C. Dale,J. de Seze,Diego Franciotta,Kazuo Fujihara,Anu Jacob,Ho Jin Kim,Ingo Kleiter,T. Kümpfel,Michael J. Levy,Jacqueline Palace,Klemens Ruprecht,Albert Saiz,Corinna Trebst,Brian G. Weinshenker,Brigitte Wildemann +19 more